Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability

Article, Review English OPEN
Cho, Hee Ju ; Yoo, Tag Keun (2014)
  • Publisher: Dove Medical Press
  • Journal: Research and Reports in Urology, volume 6, pages 113-119 (issn: 2253-2447, eissn: 2253-2447)
  • Related identifiers: doi: 10.2147/RRU.S41618, pmc: PMC4199653
  • Subject: Diseases of the genitourinary system. Urology | RC870-923 | α1A-adrenoceptor antagonist | Review | Research and Reports in Urology | lower urinary tract symptoms | silodosin | benign prostatic hyperplasia

Hee Ju Cho, Tag Keun Yoo Department of Urology, Eulji Hospital, Eulji University School of Medicine, Seoul, KoreaAbstract: α1-Adrenergic receptor antagonists are commonly used to treat male lower urinary tract symptoms and benign prostatic hyperplasia (BPH). W... View more
  • References (25)
    25 references, page 1 of 3

    1. Yoshida M, Kudoh J, Homma Y, Kawabe K. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms. Int J Urol. 2012;19(4): 306-316.

    2. Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48(2):250-258.

    3. Moriyama N, Akiyama K, Murata S, et al. KMD-3213, a novel alpha1A-adrenoceptor antagonist, potently inhibits the functional alpha1-adrenoceptor in human prostate. Eur J Pharmacol. 1997;331(1): 39-42.

    4. Akiyama K, Tatemichi S, Katayama S, et al. Relationship between prostatic alpha(1)-adrenoceptor binding and reduction in intraurethral pressure following continuous infusion of KMD-3213 in rats. Pharmacology. 2002;64(3):140-147.

    5. Tatemichi S, TomiyamaY, Maruyama I, et al. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodyn. 2006;25(7): 792-799; discussion 800-801.

    6. Choo MS, Song M, Kim JH, et al. Safety and efficacy of 8-mg oncedaily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study. Urology. 2014;83(4):875-881.

    7. Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. [Alpha1-adrenoceptor subtype selectivity and organ specicfiity of silodosin (KMD-3213)]. Yakugaku zasshi. 2006;126 Spec no:209-216. Japanese.

    8. Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T. Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002;71(21):2531-2541.

    9. Tatemichi S, Kobayashi K, Maruyama I, Kobayashi M, Yamazaki Y, Shibata N. [Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats - study of the selectivity for lower urinary tract]. Yakugaku zasshi. 2006;126 Spec no:217-223. Japanese.

    10. Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007;16(12): 1955-1965.

  • Metrics
    No metrics available
Share - Bookmark